From mboxrd@z Thu Jan 1 00:00:00 1970 Path: main.gmane.org!not-for-mail From: "Solomon J. Maddox" <maddoxjt@mitra.com> Newsgroups: gmane.emacs.devel,gmane.spam.detected Subject: Investors Profile; facts not fiction Date: Tue, 17 Aug 2004 08:57:49 +0000 Sender: emacs-devel-bounces+ged-emacs-devel=m.gmane.org@gnu.org Message-ID: <060201c48438$a4848d9e$cea94d66@hulwzmcr> NNTP-Posting-Host: deer.gmane.org Mime-Version: 1.0 Content-Type: text/plain Content-Transfer-Encoding: 8bit X-Trace: sea.gmane.org 1092732727 18989 80.91.224.253 (17 Aug 2004 08:52:07 GMT) X-Complaints-To: usenet@sea.gmane.org NNTP-Posting-Date: Tue, 17 Aug 2004 08:52:07 +0000 (UTC) Original-X-From: emacs-devel-bounces+ged-emacs-devel=m.gmane.org@gnu.org Tue Aug 17 10:51:59 2004 Return-path: <emacs-devel-bounces+ged-emacs-devel=m.gmane.org@gnu.org> Original-Received: from lists.gnu.org ([199.232.76.165]) by deer.gmane.org with esmtp (Exim 3.35 #1 (Debian)) id 1BwzhG-0002Rf-00 for <ged-emacs-devel@m.gmane.org>; Tue, 17 Aug 2004 10:51:59 +0200 Original-Received: from localhost ([127.0.0.1] helo=lists.gnu.org) by lists.gnu.org with esmtp (Exim 4.33) id 1BwzlP-0008QE-P6 for ged-emacs-devel@m.gmane.org; Tue, 17 Aug 2004 04:56:15 -0400 Original-Received: from mailman by lists.gnu.org with tmda-scanned (Exim 4.33) id 1BwzkA-00089r-7z for emacs-devel@gnu.org; Tue, 17 Aug 2004 04:54:58 -0400 Original-Received: from exim by lists.gnu.org with spam-scanned (Exim 4.33) id 1Bwzk7-000881-07 for emacs-devel@gnu.org; Tue, 17 Aug 2004 04:54:56 -0400 Original-Received: from [199.232.76.173] (helo=monty-python.gnu.org) by lists.gnu.org with esmtp (Exim 4.33) id 1Bwzk6-00087q-P5 for emacs-devel@gnu.org; Tue, 17 Aug 2004 04:54:54 -0400 Original-Received: from [60.35.107.80] (helo=netpointllc.com) by monty-python.gnu.org with esmtp (Exim 4.34) id 1Bwzfm-0000Ht-2v for emacs-devel@gnu.org; Tue, 17 Aug 2004 04:50:27 -0400 Original-To: emacs-devel@gnu.org X-BeenThere: emacs-devel@gnu.org X-Mailman-Version: 2.1.5 Precedence: list List-Id: "Emacs development discussions." <emacs-devel.gnu.org> List-Unsubscribe: <http://lists.gnu.org/mailman/listinfo/emacs-devel>, <mailto:emacs-devel-request@gnu.org?subject=unsubscribe> List-Archive: <http://lists.gnu.org/pipermail/emacs-devel> List-Post: <mailto:emacs-devel@gnu.org> List-Help: <mailto:emacs-devel-request@gnu.org?subject=help> List-Subscribe: <http://lists.gnu.org/mailman/listinfo/emacs-devel>, <mailto:emacs-devel-request@gnu.org?subject=subscribe> Errors-To: emacs-devel-bounces+ged-emacs-devel=m.gmane.org@gnu.org X-Spam-Report: 6.4 points; * 0.0 FORGED_RCVD_HELO Received: contains a forged HELO * 5.4 BAYES_99 BODY: Bayesian spam probability is 99 to 100% * [score: 1.0000] * 1.0 MSGID_DOLLARS Message-Id has pattern used in spam Xref: main.gmane.org gmane.emacs.devel:26278 gmane.spam.detected:313200 X-Report-Unspam: http://unspam.gmane.org/gmane.emacs.devel:26278 The Growth Stock Report Breaking News!! Genex Pharmaceuticals (OTCBB: GENX.OB) EARNINGS RELEASE: Genex Pharmaceutical 2nd Quarter Revenue Up 432%. Gross PR0FIT Up 380% as Genex's Net INC0ME Soars. Sees Continued Earnings Momentum for Remainder of 2004. ______________________________________________________ Monday August 16, 9:28 am ET NEW YORK-- (BUSINESS WIRE) --Aug.16, 2004 -- Genex Pharmaceutical, Inc. (Stock Symbol: GENX.OB) announced financial results for its second quarter ending June 30, 2004. The following are some of the highlights in its recent quarterly filing with the SEC: 432% in-crease in revenue for Q2 2004 compared to Q2 2003. 874% in-crease in revenue for 6 months ended June 30, 2004 compared to same period last year. Significant in-crease in net INC0ME for Q2 2004 compared to Q2 2003 and for the 6 month period ended June 30, 2004 as compared to same period last year. 380% in-crease in Gross PR0FIT for Q2 2004 compared to Q2 2003. 840% in-crease in Gross PR0FIT for 6 months ended June 30, 2004 compared to same period last year. ______________________________________________________ REVENUE For the three month period ended June 30, 2004 as compared to the three month period ended June 30, 2003, Genex generated net revenues of $525,750 and $98,763, respectively, reflecting an in-crease of $426,987 or 432%. The in-crease in revenues was primarily attributable to the commercialization of the company's main product, RBX, as well as in-creased marketing efforts, which resulted in in-creases in our customer base and related volume of recurring and new customer sales. For the six month period ended June 30, 2004 as compared to the period ended June 30, 2003, Genex generated net revenues of $961,958 and $98,763, respectively, reflecting an in-crease of $863,195 or 874%. The in-crease in revenues was primarily attributable to the commercialization of the company's main product, RBX, as well as in-creased marketing efforts, which resulted in in-creases in our customer base and related volume of recurring and new customer sales. ______________________________________________________ NET INC0ME The company's net INC0ME was $218,595 for the six months ended June 30, 2004, an in-crease of $242,524 compared to $(23,929) for the period ended June 30, 2003. The in-crease is attributed to the substantial growth in the demand for our products throughout China and continued development and implementation of our business during 2004. Net INC0ME was $151,904 for the three months ended June 30, 2004, an in-crease of $175,833 compared to ($23,929) for the three months ended June 30, 2003. The in-crease is attributed to the substantial growth in the demand for the Company's products throughout China and continued development and implementation of our business during 2004. ______________________________________________________ GROSS PR0FIT Genex achieved a gross PR0FIT of $758,040 for the six months ended June 30, 2004, an in-crease of $677,403 or 840%, compared to $80,637 for the period ended June 30, 2003. Gross margin, as a percentage of revenues, decreased from 82% for the six months ended June 30, 2003, to 79% for the period ended June 30, 2004. The decrease in gross margin was primarily attributable to commercialization of the company's main product, RBX, and in-creased sales of products. Genex achieved a gross PR0FIT of $386,750 for the three months ended June 30, 2004, an in-crease of $306,113 or 380%, compared to $80,637 for the three months ended June 30, 2003. Gross margin, as a percentage of revenues, decreased from 82% for the three months ended June 30, 2003, to 74% for the three months ended June 30, 2004. The decrease in gross margin was primarily attributable to commercialization of the Company's main product, RBX, and in-creased sales of products. "We are seeing significant in-creases in revenues and PR0FITABILITY as we respond to growing customer demand for RBX. We see continued earnings momentum for the remainder of 2004," said Chairman and Chief Executive Mr. Fuzhi Song. ______________________________________________________ About Genex Pharmaceutical, Inc. Genex Pharmaceutical, Inc. is a biomedical technology company with distinctive proprietary technology for an orthopedic device that treats bone-related injuries. Headquartered in Tianjin, China, the Company manufactures and distributes Reconstituted Bone Xenograft (RBX), to 400 hospitals in 22 provinces throughout mainland China. RBX is approved by the State Food and Drug Administration (SFDA) in China (the Chinese government agency that regulates drugs and medical devices). RBX offers a modern alternative to traditional methods of treating orthopedic injuries. Good Luck and Succesful Trading. Go GENEX!! ______________________________________________________ DISCL-AIMER: Information within this em-ail contains "F0RWARD looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "F0RWARD looking statements."F0RWARD looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. F0RWARD looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur. As with many micro-cap stocks, today's company has additional risk factors worth noting. Those factors include:a limited operating history, the company advancing cash to related parties and a shareholder on an unsecured basis: one vendor, a related party through a majority stockholder, supplies ninety-seven percent of the company's raw materials: reliance on two customers for over fifty percent of their business and numerous related party transactions and the need to raise capital.These factors and others are more fully spelled out in the company's SEC filings. We urge you to read the those filings before you invest. The Growth ST0CK Report does not represent that the information contained in this message states all material facts or does not omit a material fact necessary to make the statements therein not misleading. All information provided within this em-ail pertaining to investing, ST0CKS, securities must be understood as information provided and not investment advice. The Growth ST0CK Report advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in ST0CKS featured within this ema-il. None of the material within this report shall be construed as any kind of investment advice or solicitation.Many of these companies are on the verge of bankruptcy. You can lose all your M0NEY by investing in this ST0CK. The publisher of The Growth ST0CK Report is not a registered investment ADVIS0R. Subscribers should not view information herein as legal, tax, accounting or investment advice. Any reference to past performance(s) of companies are specially selected to be referenced based on the favorable performance of these companies. You would need perfect timing to acheive the results in the examples given. There can be no assurance of that happening. Remember, as always, past performance is never indicative of future results and a thorough due diligence effort, including a review of a company's filings, should be completed prior to investing. In compliance with the Securities Act of 1933, Section 17(b),The Growth ST0CK Report discloses the receipt of twelve thousand D0LLARS from a third party (DMI,Inc.), not an officer, director or affiliate shareholder for the circulation of this report. DMI, Inc. has a position in the ST0CK they will sell at any time without notice. Be aware of an inherent conflict of interest resulting from such compensation due to the fact that this is a paid adver-tisement and we are conflicted. All factual information in this report was gathered from public sources, including but not limited to Company Websites, SEC Filings and Company Press Releases. The Growth ST0CK Report believes this information to be reliable but can make no guarantee as to its accuracy or completeness. Use of the material within this em-ail constitutes your acceptance of these terms.